Dr. Sznol Discusses Immunotherapy Combinations in RCC

Mario Sznol, MD
Published: Friday, Jun 01, 2018



Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma (RCC).

Aside from the impressive results with ipilimumab (Yervoy) and nivolumab (Opdivo), which showed a survival benefit over sunitinib (Sutent), there are many combinations coming down the pike to treat patients with metastatic RCC. Sznol says that anti–PD-1/anti–PD-L1 inhibitors can be combined with any of the VEGF receptor inhibitors, including bevacizumab (Avastin), sunitinib, cabozantinib (Cabometyx), and lenvatinib (Lenvima). Phase III trial results for some of these combinations are expected soon.

Additionally, anti–PD-1/anti–PD-L1 inhibitors are being combined with a number of other agents, including cytokines, NKTR-214, and interleukin 15, Snzol says. Combinations of anti–PD-1/anti–PD-L1 and IDO inhibitors are also demonstrating response rates that are better than anticipated. Sznol says that phase II and phase III trials are due to read out in the near future, making the landscape of RCC very interesting.


Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma (RCC).

Aside from the impressive results with ipilimumab (Yervoy) and nivolumab (Opdivo), which showed a survival benefit over sunitinib (Sutent), there are many combinations coming down the pike to treat patients with metastatic RCC. Sznol says that anti–PD-1/anti–PD-L1 inhibitors can be combined with any of the VEGF receptor inhibitors, including bevacizumab (Avastin), sunitinib, cabozantinib (Cabometyx), and lenvatinib (Lenvima). Phase III trial results for some of these combinations are expected soon.

Additionally, anti–PD-1/anti–PD-L1 inhibitors are being combined with a number of other agents, including cytokines, NKTR-214, and interleukin 15, Snzol says. Combinations of anti–PD-1/anti–PD-L1 and IDO inhibitors are also demonstrating response rates that are better than anticipated. Sznol says that phase II and phase III trials are due to read out in the near future, making the landscape of RCC very interesting.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x